Skip to main content

Charcot-Marie-Tooth Disease clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients

    open to eligible people ages 16-65

    The purpose of this study is to determine whether PXT3003 is effective and safe in the treatment of Charcot-Marie-Tooth disease - Type 1A. This double-blind study will assess in parallel groups 1 dose of PXT3003 compared to Placebo in CMT1A patients treated for 15 months.

    at UC Davis UCLA

Last updated: